What is MannKind?
MannKind Corporation is dedicated to the development and commercialization of innovative therapeutic products and services targeting endocrine and orphan lung diseases within the United States. Its product portfolio includes Afrezza Inhalation Powder, an inhaled insulin designed to enhance glycemic control in adult diabetes patients, and the V-Go wearable insulin delivery device for continuous subcutaneous insulin infusion. Additionally, the company offers Tyvaso DPI, a treatment for pulmonary arterial hypertension and pulmonary hypertension. The company's focus on critical health areas positions it as a key player in specialized biopharmaceuticals.
How much funding has MannKind raised?
MannKind has raised a total of $1.7B across 13 funding rounds:
Corporate Investment
$150M
Stock Offering
$36.2M
Stock Offering
$47.5M
Stock Offering
$61M
Stock Offering
$28M
Debt
$2M
Stock/Share Issuance
$500M
Corporate Investment (2014): $150M led by Sanofi
Stock Issuance/Offering (2015): $36.2M, investors not publicly disclosed
Stock Issuance/Offering (2016): $47.5M, investors not publicly disclosed
Stock Issuance/Offering (2017): $61M, investors not publicly disclosed
Stock Issuance/Offering (2018): $28M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Stock/Share Issuance (2025): $500M, investors not publicly disclosed
Key Investors in MannKind
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation. The company focuses on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care. Guided by research and patient needs, it works with healthcare partners worldwide to advance sustainable and responsible healthcare solutions.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research. Deerfield also engages in philanthropic efforts through its New York City-based not-for-profit, Cure, which fosters innovative healthcare initiatives. Their collaborative approach connects people, capital, ideas, and technology to build and enhance healthcare solutions.
PPP
Public-Private Partnership
What's next for MannKind?
With a substantial enterprise-level funding context and a recent strategic investment, MannKind appears to be in a scaling phase, poised for accelerated growth and market penetration. The capital infusion is likely to fuel further research and development, potentially expanding its clinical trial pipeline and enhancing its commercialization efforts for existing and pipeline therapies. Strategic partnerships and continued innovation will be crucial for MannKind to solidify its market position and address unmet medical needs in its specialized therapeutic areas.
See full MannKind company page
